You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Paris Pearls: Updates on the Role of LAG-3 in the Metastatic Melanoma Immunotherapy Landscape

  • Authors: Michael Davies, MD, PhD; Evan Lipson, MD; Omid Hamid, MD
  • CME / ABIM MOC Released: 9/23/2022
  • Valid for credit through: 9/23/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for community-based oncologists, dermatologists, pathologists, and other healthcare professionals (HCPs) who care for people with metastatic melanoma.

The goal of this activity is for learners to be better able to understand the role of immunotherapy, with an emphasis on LAG3, and how best to incorporate immunotherapy into the treatment paradigm for patients with metastatic melanoma.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanisms of immunotherapy used in the treatment of metastatic melanoma
    • Key clinical trial data evaluating immunotherapies used to treat metastatic melanoma
  • Demonstrate greater confidence in their ability to
    • Integrate relevant immunotherapy data updates into the clinical care of patients with metastatic melanoma


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


  • Michael Davies, MD, PhD

    Professor and Chairman
    Department of Melanoma Medical Oncology
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas


    Michael Davies, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: ABM Therapeutics; Apexigen; Array; Bristol Myers Squibb; Eisai; Iovance; Novartis; Pfizer; Roche/Genentech
    Research funding from: ABM Therapeutics; LEAD Pharma

  • Evan Lipson, MD

    Associate Professor of Oncology
    Johns Hopkins University
    Baltimore, Maryland


    Participation by Dr Lipson does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

    Evan Lipson, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb; CareDx; Eisai; Genentech; Immunocore; Instil Bio; MacroGenics; Merck; Natera; Nektar Therapeutics; Odonate Therapeutics; OncoSec; Pfizer; Rain Therapeutics; Regeneron; Sanofi
    Research funding from: Bristol Myers Squibb; Merck; Regeneron; Sanofi

  • Omid Hamid, MD

    Chief of Research/Immuno-Oncology 
    The Angeles Clinic & Research Institute 
    Co-Director, Cutaneous Malignancy Program 
    Cedars-Sinai Cancer 
    Los Angeles, California 


    Omid Hamid, MD, has the following relevant financial relationships:
    Consultant or advisor for: Aduro Biotech, Inc.; Akeso; Alkermes; Amgen; BeiGene; BioAtla; Bristol Myers Squibb; GlaxoSmithKline; Idera Pharmaceuticals, Inc.; Immunocore; Incyte Corporation; Instil Bio; Iovance Biotherapeutics; Janssen; Merck; NextCure, Inc.; Novartis; Pfizer; Roche Genentech; Sanofi/Regeneron; Seagen Inc.; Tempus; Zelluna Immunotherapy
    Speaker or member of speakers bureau for: Bristol Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
    Contracted researcher for: Arcus; Aduro; Akeso; Amgen; Bioatla; Bristol Myers Squibb; CytomX Therapeutics; Exelixis; GlaxoSmithKline; Idera, Inc.; Immunocore; Incyte Corporation; Iovance Biotherapeutics; Merck; Merck Serano; Moderna; NextCure Inc.; Novartis; Pfizer; Roche Genentech; Rubius; Sanofi/Genentech; Seagen Inc.; Taiga Biotechnologies, Inc.; Torque Therapeutics, Inc; Zelluna Immunotherapy


  • Deborah Middleton, MS

    Senior Medical Education Director, WebMD Global, LLC


    Deborah Middleton, MS, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Paris Pearls: Updates on the Role of LAG-3 in the Metastatic Melanoma Immunotherapy Landscape

Authors: Michael Davies, MD, PhD; Evan Lipson, MD; Omid Hamid, MDFaculty and Disclosures

CME / ABIM MOC Released: 9/23/2022

Valid for credit through: 9/23/2023


Note: In order to facilitate disseminating this educational activity as quickly as possible, the associated slides and transcript will be included ~2-3 weeks after the activity posting date.

Contents of This CME Activity

All sections of this activity are required for credit.

Neoadjuvant Therapy for High-Risk Regionally Metastatic Melanoma

Dr Davies discusses key neoadjuvant data for high-risk regionally metastatic melanoma.
Michael Davies, MD, PhD

The Role of LAG-3 in Patients With Unresectable or Metastatic Melanoma

Dr Lipson discusses role for targeting LAG-3 in patients with unresectable or metastatic melanoma.
Evan Lipson, MD

Future Directions in the LAG-3 Landscape

Dr Hamid provides insights into the future of LAG-3 in melanoma.
Omid Hamid, MD

Learning Feedback Questions

Please answer these questions to complement your learning experience.